{"id":"W4281636766","doi":"10.1182/bloodadvances.2021006193","title":"Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; McMaster University","funders":"Kite Pharma; Chugai Pharmaceutical; Genentech; MorphoSys; SymBio Pharmaceuticals Limited; Ono Pharmaceutical; Teijin Pharma; TG Therapeutics; Kiadis Pharma; Japan Science and Technology Agency; Juno Therapeutics; Astellas Pharma; Eisai; Daiichi-Sankyo; Omeros Corporation; Pfizer; Incyte; BeiGene; Loxo Oncology; Astex Pharmaceuticals; Nippon Shinyaku; Regeneron Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Karyopharm Therapeutics; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; Celgene; Amgen; Fuji Pharma; Japan Society for the Promotion of Science; GlaxoSmithKline","keywords":"Diffuse large B-cell lymphoma; Refractory (planetary science); Lymphoma; Medicine; Term (time); Oncology; Internal medicine; Cancer research; Biology; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002027079,0.0002646341,0.0003999857,0.000151822,0.0004224969,0.0000228251,0.000234925,0.00005916246,0.00180376],"category_scores_gemma":[0.00004240799,0.0002191203,0.0001389624,0.0003486181,0.00007977811,0.0001776454,0.0001413144,0.0002224262,0.00002020456],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002022791,"about_ca_system_score_gemma":0.0001504442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001066341,"about_ca_topic_score_gemma":0.00003318676,"domain_scores_codex":[0.9977001,0.0001002292,0.0003057062,0.0005321485,0.0007427231,0.0006191035],"domain_scores_gemma":[0.9987388,0.0002096922,0.0001499658,0.0005306643,0.0001569869,0.0002139263],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01286152,0.03652911,0.8642896,0.000434879,0.000409317,0.000276709,0.0004660071,0.00000842763,0.01233169,0.00003077112,0.000523236,0.07183868],"study_design_scores_gemma":[0.1880177,0.01245489,0.3738719,0.000130742,0.0005879141,0.00006763866,0.000292015,0.00004124568,0.01959946,0.00004224927,0.4040797,0.0008145993],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923221,0.002631104,0.00006887212,0.00008274814,0.0001769831,0.001669959,0.0003442165,0.0001316413,0.0025723],"genre_scores_gemma":[0.9760363,0.0004987843,0.0003657679,0.0002701313,0.0001397026,0.0004071656,0.000724074,0.0001099919,0.02144814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4904178,"threshold_uncertainty_score":0.9991087,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009813489538978077,"score_gpt":0.2651330121369403,"score_spread":0.2553195225979622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}